Leadership Transition at BioNTech as Founders Depart for New Venture

BioNTech founders to leave by 2026, spinning out a new mRNA firm. Company maintains strong cash reserves despite declining vaccine revenue, with focus on pivotal oncology trials.

BioNTech SE is entering a pivotal new chapter as its visionary founders prepare to step down. The architects of its COVID-19 vaccine, Ugur Sahin and Özlem Türeci, will relinquish their executive roles by the end of 2026 to establish a separate mRNA-focused company. This unexpected leadership change arrives at a critical juncture for the Mainz-based firm, which is under pressure to deliver commercial results from its multi-billion euro oncology pipeline.

Financial Resilience Amid Declining Revenue

The announcement coincided with the release of annual figures, which were largely overshadowed by the management news. As anticipated, revenue for 2025 fell to €2.87 billion, driven by waning global demand for coronavirus vaccines. Management guidance for 2026 projects a further decline, with sales expected to land between €2.0 and €2.3 billion. Despite these headwinds, the company's financial position remains robust, with a substantial cash reserve of €17.24 billion on hand.

Investor reaction to the impending departure of the founding leadership was initially negative. The stock closed Friday's session at €79.60, recording a weekly decline of over 9 percent.

Strategic Spin-Out and Succession Planning

The founders' new venture will focus on next-generation mRNA innovations. Under the proposed agreement, BioNTech will contribute certain technology rights to this currently unnamed spin-off. In return, it will receive a minority equity stake and potential future milestone payments. The company has explicitly ruled out providing ongoing financial support. A binding contract is slated to be finalized by the end of the first half of 2026. Concurrently, BioNTech's supervisory board has initiated a search for successors to the executive board positions.

Uninterrupted Focus on Clinical Pipeline

Market analysts have interpreted the transition as a logical evolution for a maturing company. Some experts even suggest that fresh leadership could enhance strategic execution. Crucially, the existing clinical development portfolio remains entirely unaffected by the founders' new endeavor. The current operational landscape includes:

• Jefferies: Reduced price target to $138, maintains "Buy" rating
• Clear Street: Lowered price target from $181 to $167, maintains "Buy" rating
• 2026 R&D Budget: Planned expenditure of €2.2 to €2.5 billion
• Clinical Development: 15 Phase 3 trials planned by the end of 2026

The coming year represents a fundamental turning point for BioNTech. While the leadership transition is managed, clinical results will take center stage. Seven key data readouts from late-stage trials are expected before year-end. These outcomes will be instrumental in determining the company's pace in transitioning from a pandemic success story to an established oncology therapeutics provider.